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Prognosis is a central piece of information we would like toknow when someone is diagnosed with a disease. Prog-
nosis is affected by many factors. For a cancer, one important
aspect is the anatomic extent of the tumor, typically described
by a stage classification. Nevertheless, a stage classification
system should not be confused with a system to predict
prognosis—tumor stage is only one aspect. Prognosis is
affected by the treatment given, by patient-specific factors
(i.e., comorbidities), tumor-related factors, and others, collec-
tively known as prognostic factors.
The International Thymic Malignancy Interest Group
(ITMIG) is currently engaged in the development of a vali-
dated formal stage classification system for thymic malignan-
cies, together with the International Association for the Study
of Lung Cancer and under the auspices of the Union
International Contre le Cancer (UICC) and American Joint
Commission on Cancer (AJCC). Assessment of prognostic
factors is an important corollary to development of an
anatomic stage classification system. A review of the
current literature identifying prognostic factors is an im-
portant baseline to have for this initiative.
The study and classification of prognostic factors, in
general, is very rudimentary. Often there is confusion because
people are not clear about the outcome in question: a factor
may be prognostic relative to overall survival, to cure from
the disease, to response to treatment, etc. Prognostic factors
are often specific to a subgroup of patients and a particular
setting: factors associated with prognosis for a patient with
thymoma undergoing surgery may be different from that of a
patient with thymic carcinoma undergoing chemotherapy and
radiation. Prognostic factors can be divided into “domains” of
tumor-related factors, host factors (i.e., that would be present
in the patient even if there was no tumor), and environmental
factors (including things such as access to optimal care).
Furthermore, once we identify a prognostic factor, we imme-
diately begin trying to change the outcome to be what we
want to see (i.e., to undermine the predictive value of the
prognostic factor). Finally, there are many statistical pitfalls
and errors in the definition of prognostic factors, as discussed
in another article in this issue.1
Despite deficiencies in our level of sophistication about
the science of prognostic factors, the need to estimate future
outcomes for patients is great. This article sets out to provide
a review of the current state of affairs in the area of thymic
malignancies.
METHODS
A search was conducted for English language articles
reporting prognostic factors for survival or recurrence for
thymoma or thymic carcinoma published from January 1,
1980, to December 31, 2010. This was supplemented with a
review of reference lists of retrieved articles, recent book
chapters and review articles, and articles identified indepen-
dently by the authors. We did not evaluate prognostic factors
relative to outcomes other than overall survival or recurrence
mainly because there are only a few isolated studies.
Recurrence is probably the best measure of outcomes
for thymic malignancies, as discussed in a recent landmark
ITMIG article.2 Unfortunately, few studies have addressed
this. We included studies reporting disease-free survival in
the analysis for recurrence, even though it is problematic to
view a recurrence and (unrelated) death as equal end points.2
Overall survival has been the most commonly used end point
because it is easy to measure. Nevertheless, is not an ideal
end point, because many patients with thymoma die of
unrelated causes, and patients may survive for many years
with recurrent disease.2 Different studies have used different
measures (e.g., overall survival and thymoma-specific sur-
vival), which can give quite different survival results. Nev-
ertheless, as the analyses were designed to evaluate the
relative prognostic value of different factors within a study, it
is reasonable to combine the prognostic factor results from
studies involving various survival measures.
A valid prognostic factor must have independent sig-
nificance and, therefore, must be evaluated in conjunction
with other factors. Because of this, only studies that reported
multivariate analysis (MVA) were included. No restriction
was placed on the method of MVA or the number or nature
of factors considered. Nevertheless, only articles reporting
on 75 patients were included. This is because a rough
estimate suggests that at least 75 patients are needed to be
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able to assess three factors with a medium effect size at a
power of 80%.2
We included studies reporting on a broad group of
patients, who were mostly treated with surgery and some-
times additional modalities. To have an assessment of the
patients involved, we included the rates of treatment with
different modalities in the tables. Separate consideration of
particular subgroups and settings in these studies is not
possible, partly because of how the reported studies were
done, and partly because the rarity of the disease precludes an
appropriate statistical analysis of many subgroups. Further-
more, studies reporting on a specific cohort are so limited that
it is difficult to draw any conclusions. Nevertheless, several
studies reported an analysis including all patients and only
resected patients; data from both were included.
We excluded duplicate publications or articles involv-
ing smaller cohorts that were subsequently also included in a
larger updated cohort. Some institutions reported results on
partially overlapping cohorts in which each article included
some unique patients; in this case, we included both articles
even though there was substantial overlap.
Data were extracted into tables, and factors were re-
corded as positive if reported to have a p value of 0.05 by
MVA. Depending on how a MVA is conducted, there may
be a high chance of false-positive results.2 For example, the
way a variable is divided (e.g., dichotomized) into groups for
analysis also often results in an overly optimistic assessment
of statistical significance (e.g., choosing the threshold by the
best separation and then entering the variable into the multi-
variate model this way, which is known as “double-dip-
ping”).1,2 As a crude approach to assessment of this risk, we
grouped those studies in the tables in which dichotomization
seems to have been done in a way associated with a risk of
false-positive designation of a prognostic factor. It was not
feasible to go beyond this to assess the actual risk.
There is also a chance of false-negative results, espe-
cially in studies of limited size, because the power of detection
is low. Data were recorded as negative if reported as such with
a p value of more than 0.05. A crude estimate of the ability to
detect a difference according to the size of the study, number of
factors analyzed, and the magnitude of the difference can be
made.2 We established a priori that to be counted as a
negative result the study should have, as a minimum by this
crude estimate, a power of detection of 80% for a medium
effect size. In the end, however, we found that all studies of
more than 75 patients satisfied this requirement.
Not all studies analyzed the same factors. Although the
assessment of significance can be strongly influenced by
which factors are left out of the analysis, no attempt was
made to correct for this. We sought to be as inclusive as
possible, and therefore, data were retrieved and accepted
as reported. The reported data were recorded as positive,
negative, or not assessed to provide a general overview of
reported results. Furthermore, most reported series chose to
dichotomize variables but not always at the same threshold.
In an effort to be inclusive, we tried to combine the data if the
thresholds were reasonably similar (and noted differences in
the footnotes of the tables).
Some studies reported several multivariate analyses
(e.g., by including or not including some factors or using
different definitions). Again, to be inclusive and in the ab-
sence of criteria to define one as more valid than another, we
included each as a separate entry in the tables. In addition,
multivariate analyses in several of the studies were specifi-
cally done or redone excluding a particular factor because it
had a dominant effect or was correlated to another factor, to
study the value of a particular factor of interest.3–8 This
would seem to undermine the purpose of MVA to sort out
which factors have the most important influence on survival
and bias the study toward finding prognostic value (falsely?)
in the factor of interest. When such studies did not report an
analysis including all factors, we were forced to include all
subset analyses (e.g., stage without histology or histology
without stage). By including all subset analyses, we hoped to
represent a more unbiased overall picture. Nevertheless, this
illustrates the potential for bias in how studies are conducted.
One study was excluded because a separate MVA was re-
ported for practically each factor, tailored to exclude other
factors that “hid” the significance of the factor of interest.3
Because this study reported no overall MVA, the reported
results were felt to be biased and were reported without
sufficient detail to even be sure what had or had not been
included in each.
To summarize the data, we calculated the percentage of
multivariate studies that found a factor to be significant out of
the number that analyzed it. This should be interpreted
cautiously and qualitatively, because of the many reasons for
false-positive and false-negative results that we cannot sort
out from this literature review. Factors that were addressed in
less than five and less than three studies of overall survival or
recurrence, respectively, are not listed in the tables because
the data are too limited to draw any meaningful conclusions.
RESULTS
The literature search and inclusion criteria outlined
earlier resulted in a total of 29 studies reporting a MVA of
prognostic factors for survival and 12 reporting this for
recurrence. A few studies4,8,9 reported more than one analy-
sis; each of these analyses were included in the tables (in
accordance with the criteria outlined in the Methods section).
The results from the included studies are summarized in
Tables 1 and 2 and Figures 1 and 2.
The patients included are not clearly described in most
of studies. Nevertheless, they can be loosely thought of as the
patients presenting to an institution for curative-intent treat-
ment. Data regarding the treatment received are summarized
in the tables. The majority of patients underwent surgery,
approximately half also received radiotherapy (RT), and
approximately 25% chemotherapy. A few studies deserve
special mention: de Jong et al.11 involved a population-based
cohort in the Netherlands, Cowen et al.22 involved only
patients treated with RT, and in the series by Lucchi et al.,25
all patients had myasthenia gravis (MG).
The factor most consistently identified as significant—
for both recurrence and survival—is the stage. In most of
studies, this was dichotomized as stages I and II versus III
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TABLE 1. Multivariate Analysis of Factors Predicting Better Survival
Study n
Treatment
(%) Factors Predicting Better Survival
No. of
Additional
FactorsR0 Ch RT
Stage
I, II R0
Hist
Thym
Hist
w/TC
Older
Agea
Small
Size
Male
Gender MG
Studies with more robust statistical approaches
Ruffini 1010b 255 87 2 45 0.001 — NS — — — — NS —
de Jong 0811c 232 41 10d 33d 0.01 — — 0.001 0.001e — NS NS 1
Rieker 026 218 77 14 39 0.001 — — 0.03 NS NS NS NS 2
Park 0412 150 69 — — 0.001 — — 0.02 NS — NS NS —
Venuta 9713b 148 — 33d — 0.0001 — NSf — 0.001 — — — 2
Park 0412 133 77 — — 0.006 NS — NS NS — 0.04 NS —
Kim 057g 108 82 16 28 0.03 NS — NS NS NS NS NS —
Studies with less robust or unclear statistical approaches
Kondo 0314b 1093 — — — 0.001 0.001 NSf — NS — NS NS 3
Margaritoria 1015 317 93 — 38 NS 0.001 — NS NS — NS NS 2
Regnard 969 307 85 6 52 NS 0.00001 — NSf — — — NS —
Lewis 8716b,g 283 83 2 26 0.05 0.05 NSf — 0.05 NS NS NS 5
Regnard 969 260 100 6 52 0.00001 — — NSf — — — NS —
Okumura 0217b,g 243 95 10d 60d 0.0001 NS 0.05 — NS — NS NS 1
Ströbel 0418g 228 67 17 32 0.05 0.05 — 0.05 NS NS NS NS 1
Fang 0519 204 88 — — 0.001 0.004 — 0.001 — — — NS —
Lee 0720 195 83 5 40 0.001 NS — 0.001 NS — NS NS —
Rena 0521b 178 84 13 43 0.04d 0.02 0.03 — NS — NS NS 1
Cowen 9522b,h 149 42 50 100 NS (0.003)i — — 0.013 0.001j — NS 1
Wilkins 9923 136 68 7 37 NSk 0.001 — 0.02f 0.036e — NS 0.005 4
Nakagawa 034b,g 130 95 4 5 0.01 NS — — NS 0.01 NS NS —
Nakagawa 034b,g 130 95 4 5 — 0.002 0.01 — NS 0.001 NS NS —
Rea 0424 132 82 18 47 0.003 NS — 0.0001 NS — NS NS 2
Lucchi 0925b,l 123 95 17 73 0.04m — NS — NS NS NS — 2
Blumberg 9526 118 73 32 58 0.003 0.0006 — 0.004f NS 0.0001 NS NS —
Pan 9427b 112 80 — — 0.05 — NS — — — — — —
Quintanilla 9428b 105 100 0 24 0.05 — 0.05f — NS NS NS NS 1
Zisis 058b 104 100 14 63 — — 0.05 — NS — NS NS 2
Zisis 058b 104 100 14 63 0.05 — — — 0.02e — NS NS 2
Kondo 0429 100 84 28 37 0.04 0.05 — NS NS — NS NS —
Kim 1030n 100 79 7 67 NS — NS — — NS — — —
Kim 0831h 100 78 45 100 0.04 NS — 0.02 0.03 — NS NS 4
Chalabreysse 025 90 67 3 12 — — — 0.001 NS — — NS —
Rieker 0732 77 74 30d 62 NS 0.001 — 0.001 NS — NS NS 1
Summary: % positiveo 83% 63% 42% 67% 15/11%p 36% 4% 3%
Inclusion criteria: Studies from 1980 to 2010 of 75 patients reporting multivariate analysis of prognostic factors. Factors evaluated by 5 studies are not listed. Studies with “less
robust statistical approaches” have used “double-dipping” methods to define dichotomization that carry a risk of a false-positive identification of a statistically significant result.
a Variously defined as 30 (Lewis, Cowen), 60 (Venuta), 47 (Park), 57 (Wilkins, Kondo, Rieker), 52 (Rena) or unspecified.
b Thymic carcinoma excluded.
c Population-based study.
d Estimated, not specifically reported.
e In this series, older age groups had significantly worse survival.
f Older, non-World Health Organization classification.
g Thymoma-specific survival.
h RT-based series.
i Biopsy only vs. resection .
j Defined as no mediastinal compression.
k Stage I vs. II–IV.
l MG-based series.
m Definition unclear.
n For thymoma type B only.
o Excluding values in parentheses.
pAssociated with better survival in 15% and worse survival in 11%.
Ch, chemotherapy; Hist, histologic type; MG, myasthenia gravis; NS, not significant; R0, complete resection; RT, radiotherapy; w/TC, with thymic carcinoma; Thym, thymoma.
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and IV. In most of studies, Masaoka or Masaoka-Koga
staging was used, and, in fact, in all staging systems, this
dichotomization yields essentially the same cohorts of pa-
tients. It should be explicitly noted, however, that most of
these multivariate analyses have not defined prognostic sig-
nificance for stage I versus II, II versus III, III versus IVa, or
for a sequential progression to worsening outcomes from I to
IVb. Nevertheless, multiple studies do show progressively
worse rates of recurrence and survival,35 although questions
have been raised whether the difference between stages I and
II is significant.36 Nevertheless, despite the limitations of
these prognostic factor studies, it seems reasonable to view
the stage of disease as a validated prognostic factor.
Another fairly consistent prognostic factor for both
recurrence and survival is a complete resection. Obviously, it
only makes sense to assess this factor in patients who are
treated with surgery (i.e., a subgroup of all patients). Despite
the fact that the rate of complete resection is clearly associ-
ated with tumor stage,35 an R0 resection seems to carry
independent significance by MVA.
The histologic subtype of thymic malignancy also
seems to be important but is a bit more difficult to fully
assess. First, different histologic classification schemes have
been used, although more recently the World Health Organi-
zation system37,38 has been the predominant one. Second is
the issue of interobserver variation in assigning the histologic
class.39–41 The greatest problem comes from the fact that
most studies reporting prognostic value for histologic typing
have not reported exactly which subtypes account for the
difference. Furthermore, the dichotomization used in most
studies has been first chosen to maximize the difference and
then tested for significance (i.e., double dipping). Uneasiness
about the strength of the results is also fostered by the fact
that the “best” dichotomization has yielded many different
cutpoints in these studies. Thymic carcinoma seems quite
consistently to have the worst survival, but whether this
subtype has independent prognostic significance cannot be as-
sessed from the data reported. We attempted to explore this by
separating the MVA in cohorts that included or excluded thymic
carcinoma. This shows that more studies including thymic car-
cinoma found prognostic significance (67%) for overall survival
than if only thymoma was included (42%). Nevertheless, there is
less difference when assessing recurrence.
TABLE 2. Multivariate Analysis of Factors Predicting Lower Rates of Recurrence or Disease-Free Survival
Study n
Treatment
(%) Factors Predicting a Lower Recurrence Rate
No. of
Additional
Factors% R0 Ch RT
Stage
I, II R0
Hist
Thym
Hist
w TC
Older
Age
Small
Size Gender MG
Studies with more robust statistical approaches
Ruffini 1010a,b 255 87 2 45 0.001 — NS — — — — NS —
Rieker 026a 218 77 14 39 0.05 — — 0.05 NS NS NS NS 2
Wright 0533 179 90 — — 0.0001 NS — 0.003 NS 0.001 NS NS 3
Huang 0934 112 73 67 43 (NS)c 0.001 — 0.006 NS NS NS — 2
Studies with less robust or unclear statistical approaches
Margaritoria 1015a 317 93 — 38 0.001 NS — NS NS — NS NS 2
Margaritoria 1015a 295 100 — 36 0.001 — — 0.003 NS — NS 0.0001 2
Rena 0521a,b 178 84 13 43 0.01 0.0001 0.02 — NS — NS NS 1
Cowen 9522b.d 149 42 50 100 0.04 (0.003)e — — 0.006 0.001f — NS 1
Blumberg 9526 118 73 32 58 0.03 NS — NS NS NS NS NS —
Quintanilla-Martinez28a,b 105 100 0 24 0.03 — 0.03g,h — NS NS NS NS 1
Kondo 0429a 100 84 28 37 0.002 0.05 — NS NS — NS NS —
Kim 1030a,b,i 100 79 7 67 0.002 — NS — — 0.002 — — —
Kim 0831a,d 100 78 45 100 0.04 NS — 0.01 NS — NS NS 3
Summary: % positivej 100% 43% 50% 63% 9% 43% 0% 9%
Inclusion criteria: studies from 1980 to 2010 of 75 patients reporting multivariate analysis of prognostic factors. Factors evaluated by 3 studies are not listed. Studies
with “less robust statistical approaches” have used “double-dipping” methods to define dichotomization that carry a risk of a false-positive identification of a statistically
significant result.
a Disease-free survival.
b Thymic carcinoma excluded.
c III vs. IV.
d RT-based series.
e Biopsy only vs. resection.
f Defined as no mediastinal compression.
g Older, non-WHO classification.
h Medullary, mixed, or cortical thymomas had lower recurrence rates than well-differentiated thymic carcinoma (undifferentiated thymic carcinoma was excluded from the
analysis).
i For thymoma type B only.
j Excluding values in parentheses.
Ch, chemotherapy; Hist, histologic type; MG, myasthenia gravis; NS, not significant; R0, complete resection; RT, radiotherapy; w/TC, with thymic carcinoma; Thym,
thymoma.
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The impact of age seems to be low. Age does not seem
to have an impact on recurrence. One might predict that if
there is no effect on recurrence, then older age would predict
worse survival due to death from other causes. Nevertheless,
several studies have found older age to be a good prognostic
factor for overall survival, and a similar number found it pre-
dicted worse survival. The age threshold has been chosen at various
cutpoints. Given the conflicting results, it is probably best to regard
this factor as unlikely to be a valid prognostic factor.
A smaller tumor was found to be a good prognostic
factor in a minority of studies for both recurrence and
survival. Factors that do not seem to have prognostic signif-
icance for either survival or recurrence are gender and the
presence of MG.
Many additional factors have been investigated sporad-
ically (5 studies). For overall survival, these include the
time period (dichotomized periods),11,13,15,16 the development
of a recurrence,8,18,24,31 the presence of parathymic syn-
dromes other than MG,14,16,21,24 symptoms,16,23 comorbid-
ity,6,15 lymphoid hyperplasia,6,28 remission of MG,8,42 adju-
vant RT,9,42 adjuvant chemotherapy,22 RT dose,31 the
presence of another nonthymic cancer,23 great vessel involve-
ment,17 pleural invasion,31 development of nodal metasta-
ses,14 distant metastases,14 Myasthenia Gravis Foundation of
America (MGFA) class,42 performance of a preoperative
biopsy,23 race,23 cellular atypia or mitotic figures,16 perfor-
mance status,32 and the sequence of multimodality treat-
ment.31 All these investigated factors were not found to be
prognostically significant with the exception of one of four
studies examining the time period,13 one of four studies
examining the appearance of a recurrence,31 one of two
studies examining remission of MG,42 and one of one study
examining the presence of great vessel involvement.17
Additional prognostic factors that have been investi-
gated relative to recurrence (disease-free survival) in less than
three studies include the time period,15,33 performance of a
preoperative therapy,34 the use of adjuvant chemotherapy,22
the sequence of multimodality treatment,31 RT dose,31 the
presence of comorbidity,6,15 parathymic syndromes other
than MG,21,33 lymphoid hyperplasia,6,28 invasion of a vessel
or structure,33 pleural invasion,31 and race.34 All these factors
were negative for prognostic significance except pleural in-
vasion (in a single study).31
DISCUSSION
A conceptual framework to classify and integrate prog-
nostic factors into a useful system is currently not available,
and the thinking about how to approach this is evolving. The
statistical approaches to define valid prognostic factors are
much more developed, although not widely appreciated. Be-
cause the desire and need to predict outcomes are great,
definition of prognostic factors cannot be simply delayed
until the appropriate framework has been developed. Never-
theless, we must remember to view the definition of prog-
nostic factors as an evolving process and take what we have
at present with a grain of salt.
We attempted to address statistical weaknesses of ex-
isting studies to keep the results in proper perspective, but the
ability to do this was limited. Overall, the methods used in
most of the available studies carry a risk of identifying
false-positive prognostic factors, which might not stand up to
a more rigorous analysis. A review of the tables, however,
suggests similar results in the studies with more versus less
robust statistical approaches. Regarding false-negative re-
FIGURE 1. Factors associated with increased survival by
multivariate analysis. Percentage of studies finding a factor
prognostically significant for survival in multivariate analysis
in studies of 75 patients from January 1, 1980, to Decem-
ber 31, 2010. *Percentage of patients showing that older
patients had worse (not increased) survival. Hist, histologic
typing; MG, myasthenia gravis; MVA, multivariate analysis;
N, number of studies examining this factor; St, stage; Thy
Ca, thymic carcinoma; w/o, without.
FIGURE 2. Factors associated with decreased recurrence by
multivariate analysis. Percentage of studies finding a factor
prognostically significant for recurrence or disease-free sur-
vival in multivariate analysis in studies of 75 patients from
January 1, 1980, to December 31, 2010. Hist, histologic typ-
ing; MG, myasthenia gravis; MVA, multivariate analysis; N,
number of studies examining this factor; St, stage; Thy Ca,
thymic carcinoma; w/o, without.
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sults, we did not find that any reported analyses had a very
limited power of detection because of trying to evaluate too
many factors in a limited data set. Nevertheless, it should be
noted that the size of the reported studies allows only detec-
tion of prognostic factors with a medium or large effect; the
presence of a small effect on prognosis cannot be excluded
for any factor.
Many of these studies spanned 20 or more years. Only
a few studies analyzed the effect of the time period of
treatment as a prognostic factor11,13,15,16,33; only one found a
statistically significant difference.13 Nevertheless, the ambi-
guities introduced by changes in practice over time and by
inconsistencies in how various aspects of thymic malignancy
have been defined reinforce the need to view this analysis of
prognostic factors as preliminary.
The available data suggest that stage and completeness
of resection can be viewed as validated prognostic factors.
Furthermore, gender and the presence of MG can be accepted
as not having prognostic significance. The effect of tumor
size warrants further study. There are issues regarding what
threshold to use (or series of thresholds?). Furthermore, there
are issues of how size should be measured in a tumor that is
typically not a round sphere.
The effect of tumor histology also requires further
study. Survival curves from individual studies demonstrate
quite consistently that thymic carcinoma carries a worse
prognosis. Furthermore, this entity has been well recognized
in all histologic classification systems. The multivariate stud-
ies that have included thymic carcinoma fairly consistently
show prognostic value to histologic classification, whereas it
is less clearly so when these patients are excluded. A discus-
sion of issues associated with the histologic classification of
thymic malignancies is currently ongoing. Therefore, it seems
reasonable not to go beyond viewing thymic carcinoma as a
validated independent negative prognostic factor and await
further investigation before declaring other histologic fea-
tures to be prognostically significant or not.
Because of the behavior of thymic malignancies, recur-
rence is a better measure of outcomes than overall survival. In
general, the data on prognostic factors for recurrence (Ta-
ble 2) parallel those for overall survival (Table 1). Neverthe-
less, the majority of studies have used disease-free survival as
an end point, and this may at least partly explain the similar
results. It is not wise to count death (from any cause) as the
same as the development of a recurrence. Only four studies
have focused specifically on recurrence.22,26,33,34 This is
clearly an area that must be addressed by future research on
prognostic factors.
CONCLUSION
A review of the available data regarding MVA of
prognostic factors in thymic malignancies demonstrates many
limitations in our understanding of these. Tumor stage and
completeness of resection are important for overall survival,
whereas gender and the presence of MG are not. The effect of
histologic classification other than identification of thymic
carcinoma is unclear, as is the effect of tumor size. Future
research on prognostic factors needs to focus on predictors of
recurrence. Future research also should investigate novel
factors such as biomarkers, as the number of factors that
have been examined so far is rather limited. The infra-
structure developed by ITMIG should significantly facili-
tate such investigations.
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